



29 March 2023

**Proteome Sciences plc  
("Proteome Sciences" or the "Company")**

**Notice of Results**

The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance, and on the outlook for 2023, at the time of announcing the 2022 full year results which are scheduled for announcement on Tuesday 4 April 2023.

**For further information please contact:**

**Proteome Sciences plc**

Dr. Mariola Soehngen, Chief Executive Officer  
Dr. Ian Pike, Chief Scientific Officer  
Richard Dennis, Chief Commercial Officer  
Abdelghani Omari, Chief Financial Officer

Tel: +44 (0)20 7043 2116

**Allenby Capital Limited (Nominated Adviser & Broker)**

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

**About Proteome Sciences plc. ([www.proteomics.com](http://www.proteomics.com))**

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available